#Hong Kong #Ascletis #ASC30 #EASD

Ascletis to Unveil ASC30 Study Results at EASD 61st Annual Meeting

Ascletis Pharma Inc., a Hong Kong-based biotechnology company, is set to present findings from its significant 28-day multiple ascending dose study involving its innovative oral small molecule GLP-1 receptor (GLP-1R) agonist, ASC30. This presentation will take place during a short oral discussion at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD). The meeting is scheduled for September 15 to 19, 2025, in Vienna, Austria, with the oral presentation specifically occurring on September 16 at noon.

Study Background and Insights

The focus of the study presented by Ascletis will shine light on ASC30's efficacy in promoting weight loss among participants suffering from obesity. Notably, the abstract titled “ASC30, an oral GLP-1R biased small molecule agonist demonstrated superior weight loss in participants with obesity a 28-day multiple ascending dose study” encapsulates the research's intent to establish ASC30 as a compelling option for managing obesity effectively.

Jinzi Jason Wu, Ph.D., the Founder, Chairman, and CEO of Ascletis, expressed optimism regarding the study outcomes, stating, “We look forward to presenting our ASC30 oral tablet clinical data to the community at this year's EASD Annual Meeting. We believe that these efficacy and safety data will position ASC30 oral tablet as a potentially differentiated option for the treatment of obesity.”

About ASC30

ASC30 represents a pioneering investigational compound that is unique in its properties, designed for both oral tablet consumption and subcutaneous injections, thus providing flexibility in administration. As a new chemical entity (NCE), ASC30 enjoys patent protection in the U.S. and globally until 2044, ensuring a robust research and commercialization pathway.

EASD Annual Meeting Overview

The EASD Annual Meeting stands as a prominent event in the diabetes research community, showcasing cutting-edge clinical research, transformative findings, and fostering invaluable dialogue among experts. Ascletis’s presence at this global conference underscores the company's commitment to advancing treatment for diabetes and obesity through innovative approaches.

Future Prospects

In addition to the presentation of ASC30, Ascletis is on track to release topline data from its Phase IIa clinical study involving ASC30 targeted at individuals dealing with obesity or excess weight. This next-stage trial is anticipated to yield results in the latter part of 2025, potentially propelling ASC30 forward as a viable treatment option in a landscape that desperately requires effective solutions for weight management.

About Ascletis Pharma Inc.

Ascletis is a fully integrated biotechnology firm dedicated to innovating and commercializing advanced therapeutics aimed at managing metabolic diseases. By leveraging proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) technology, Ascletis has successfully developed several in-house drug candidates, with ASC30 being at the forefront of its research agenda. Ascletis, listed under HKEX 1672, continues to push the envelope in biochemical innovation, emphasizing efficacy and patient safety in all its offerings.

To learn more about Ascletis and its initiatives, interested professionals and stakeholders can visit their official website at www.ascletis.com.